| OPINION |
|
| Year : 2021 | Volume
: 3
| Issue : 2 | Page : 51-53 |
|
|
Ischemic preconditioning for the treatment of COVID-19: Not only protection from cardiac ischemia
Elpidio Santillo
Geriatric Rehabilitative Department, Rehabilitative Cardiology Unit, Italian National Research Center on Aging (IRCCS-INRCA), Contrada Mossa 2, 63900 Fermo, Italy
Correspondence Address:
Dr. Elpidio Santillo
Geriatric Rehabilitative Department, Rehabilitative Cardiology Unit, Italian National Research Center on Aging (IRCCS-INRCA), Contrada Mossa 2, 63900 Fermo
Italy
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/ACCJ.ACCJ_34_20
|
|
|
Ischemic preconditioning (IPC) is an innate mechanism of tissue protection from ischemia, which is easily replicable in clinical settings in the form of remote IPC. The final protective effect of IPC comprises the induction of favorable anti-inflammatory and anti-thrombotic molecular pathways. Recent studies on humans have confirmed that IPC protocols may exert cardioprotective actions. Moreover, IPC was also found to be capable of reducing surgical lung injury through the contrast of inflammatory response. Hence, IPC seems an ideal candidate to be tested as an innovative therapeutic weapon against a disease as coronavirus disease 19 (COVID-19), in which inflammation plays a key role. Interestingly, the use of IPC protocols for COVID-19 patients, beyond the potentiality of reducing the cardiologic complications, could also prove useful for the attenuation of inflammatory phenomena that characterize the course of coronavirus disease.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
